Friday
SESSION 84: NEW DEVELOPMENTS AND UPDATES REGARDING CCSVI IN MULTIPLE SCLEROSIS; USE OF DRUGS IN VASCULAR DISEASE PATIENTS AND WAYS TO PREDICT RISKS OF ADVERSE EVENTS
SESSION 84 SCHEDULE
CCSVI
2:08 PM - 2:13 PM Multicenter Blinded RCT To Determine Safety And Effectiveness (Quality Of Life) Of Venous PTA For Multiple Sclerosis (The BRAVE DREAMS Trial): Design And Progress: Will It Settle The Controversy
  Presenter(s):Paolo Zamboni, MD  
  View Slides in PDF      
DRUG TREATMENT OF VASCULAR DISEASES
2:14 PM - 2:19 PM How Can Statins And Other Medical Treatment Decrease The Amputation And Major Adverse Limb Event Rates After Revascularizations For CLI: What Are The Optimal Drugs And Dosages
  Presenter(s):Patrick A. Stone, MD / Aravinda Nanjundappa, MD  
  View Slides in PDF      
2:20 PM - 2:25 PM Optimal Use Of ACE Inhibitors, Cilostazol, And Statins In Patients Undergoing Open And Endovascular Procedures
  Presenter(s):Anthony J. Comerota, MD, FACS, FACC  
  View Slides in PDF      
2:26 PM - 2:31 PM Update On When And How Should Beta Blockers Be Used In Low Risk And High Risk Vascular Patients Generally And When They Undergo Operations And Interventions: Dosage Is Key
  Presenter(s):Caron B. Rockman, MD / Jeffrey S. Berger, MD, MS, FAHA, FACC   
  View Slides in PDF      
2:32 PM - 2:37 PM Improving Non-Coronary Stent Outcomes By Pharmacological Manipulations 2C19 And Plavix: How Do They Do It
  Presenter(s):Karthikeshwar Kasirajan, MD  
  View Slides in PDF      
2:38 PM - 2:43 PM What Is New In Antiplatelet Treatment Of Vascular Patients: Which Drugs In Which Situation: New Drugs And What Does The EUCLID Trial Tell Us
  Presenter(s):Jeffrey S. Berger, MD, MS, FAHA, FACC  / Caron B. Rockman, MD  
  View Slides in PDF      
2:44 PM - 2:50 PM Panel Discussion
Moderator(s): Anthony J. Comerota, MD, FACS, FACC / Elliot L. Chaikof, MD, PhD  
2:50 PM - 2:55 PM Benefits Of Perioperative Statins In Improving Outcomes And Decreasing Adverse Events After AAA And Carotid Procedures Endo And Open: Optimal Timing, Drug And Dosage
  Presenter(s):Bruce A. Perler, MD, MBA  
  View Slides in PDF      
2:56 PM - 3:01 PM Update On The Medical (Drug) Treatment Of AAA Disease: What Does Metformin Do: Does Any Drug Slow AAA Growth
  Presenter(s):Ronald L. Dalman, MD  
  View Slides in PDF      
3:02 PM - 3:07 PM Should Bivalirudin Replace Heparin In Non-Cardiac Interventions: Advantages And How To Use It
  Presenter(s):George H. Meier III, MD  
  View Slides in PDF      
VALUE OF TESTS
3:08 PM - 3:13 PM Biomarkers Can Predict Long-Term (~10 Years) Adverse Cardiovascular Events In Vascular Patients: Which Ones And How Can They Be Used
  Presenter(s):Beatrice R. Amann-Vesti, MD  
  View Slides in PDF      
3:14 PM - 3:19 PM How To Identify Patients At Risk Of Cardiovascular Adverse Events After EVAR
  Presenter(s):Janet T. Powell, MD, PhD  
  View Slides in PDF      
3:20 PM - 3:26 PM Panel Discussion
3:26 PM - 3:36 PM Break Visit Exhibits And Pavilions (2nd and 3rd Floors)
END OF SESSION 84
previous next